Interstitial Cystitis

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

1100%

+ 19 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AbbVieNORTH CHICAGO, IL

4 programs

Onabotulinumtoxin APhase 41 trial

LiRIS 400 mgPhase 21 trial

Lidocaine Releasing Intravesical System - LiRIS®Phase 21 trial

LiRIS low dose and LiRIS high dosePhase 11 trial

Active Trials

NCT01150565Completed18Est. Sep 2011

NCT01824303Terminated31Est. Dec 2014

NCT01475253Terminated104Est. Dec 2012

+1 more trials

Prevail TherapeuticsNY - New York

2 programs

VNX001Phase 21 trial

Active Trials

NCT06394830Recruiting50Est. Jun 2026

NCT05737121Recruiting120Est. Jun 2026

VaneltixNJ - New Brunswick

2 programs

VNX001Phase 2

Lipella PharmaceuticalsPITTSBURGH, PA

1 program

LP-08 80mgPhase 21 trial

Active Trials

NCT01393223Completed21Est. Jun 2018

PfizerNEW YORK, NY

1 program

PD 0299685 at 15mg BIDPhase 21 trial

Active Trials

NCT00739739Completed161Est. Jan 2010

SeikagakuJapan - Ibaraki

1 program

SI-722Phase 1/21 trial

Active Trials

NCT04208087Completed33Est. Jan 2021

BiocorpFrance - Issoire

1 program

MR-MC-01Phase 11 trial

Active Trials

NCT04610359Unknown3Est. Dec 2022

Colorado TherapeuticsCO - Louisville

2 programs

Trans-MAPP II Study of Urologic Chronic Pelvin PainN/A1 trial

Trans-MAPP Symptom Patterns Study (SPS)N/A1 trial

Active Trials

NCT02898220Completed72Est. Jun 2022

NCT02514265Completed640Est. Jun 2020

Grace MedicalTN - Memphis

1 program

FospropofolN/A1 trial

Active Trials

NCT01378754Withdrawn0Est. Jun 2014

MedtronicNJ - Phillipsburg

1 program

InterstimN/A1 trial

Active Trials

NCT00590473Completed32Est. Feb 2009

MicroGenDXTX - Lubbock

1 program

Polymerase Chain Reaction and Next-Generation DNA SequencingN/A1 trial

Active Trials

NCT05276466Unknown100Est. Dec 2023

Ironwood PharmaceuticalsMA - Boston

1 program

IW-3300 rectal foamPHASE_21 trial

Active Trials

NCT05740007Terminated98Est. Feb 2025

MediciNovaLA JOLLA, CA

1 program

MN-001 BIDPHASE_21 trial

Active Trials

NCT00295854Completed296Est. Oct 2006

TevaIsrael - Petach Tikva

1 program

fremanezumabPHASE_2Monoclonal Antibody1 trial

Active Trials

NCT04447729Withdrawn0Est. Feb 2022

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

AbbVieOnabotulinumtoxin A

Prevail TherapeuticsVNX001

Ironwood PharmaceuticalsIW-3300 rectal foam

Tevafremanezumab

Lipella PharmaceuticalsLP-08 80mg

AbbVieLiRIS 400 mg

AbbVieLidocaine Releasing Intravesical System - LiRIS®

PfizerPD 0299685 at 15mg BID

MediciNovaMN-001 BID

SeikagakuSI-722

BiocorpMR-MC-01

AbbVieLiRIS low dose and LiRIS high dose

MicroGenDXPolymerase Chain Reaction and Next-Generation DNA Sequencing

Colorado TherapeuticsTrans-MAPP II Study of Urologic Chronic Pelvin Pain

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 1,806 patients across 18 trials

NCT02297100 AbbVieOnabotulinumtoxin A

Intravesicular Onabotulinumtoxin A in Interstitial Cystitis

Start: Dec 2014Est. completion: Jan 201827 patients

Phase 4Completed

NCT06394830 Prevail TherapeuticsVNX001

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

Start: Dec 2024Est. completion: Jun 202650 patients

Phase 2Recruiting

NCT05737121 Prevail TherapeuticsVNX001

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Start: May 2023Est. completion: Jun 2026120 patients

Phase 2Recruiting

NCT05740007 Ironwood PharmaceuticalsIW-3300 rectal foam

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Start: Mar 2023Est. completion: Feb 202598 patients

Phase 2Terminated

NCT04447729 Tevafremanezumab

A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome

Start: Oct 2020Est. completion: Feb 20220

Phase 2Withdrawn

NCT01393223 Lipella PharmaceuticalsLP-08 80mg

Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome

Start: Jul 2015Est. completion: Jun 201821 patients

Phase 2Completed

NCT01824303 AbbVieLiRIS 400 mg

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Start: Mar 2013Est. completion: Dec 201431 patients

Phase 2Terminated

NCT01475253 AbbVieLidocaine Releasing Intravesical System - LiRIS®

Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

Start: Nov 2011Est. completion: Dec 2012104 patients

Phase 2Terminated

NCT00739739 PfizerPD 0299685 at 15mg BID

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

Start: Aug 2008Est. completion: Jan 2010161 patients

Phase 2Completed

NCT00295854 MediciNovaMN-001 BID

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

Start: May 2005Est. completion: Oct 2006296 patients

Phase 2Completed

NCT04208087 SeikagakuSI-722

PK and Safety of SI-722 in IC/BPS

Start: Mar 2020Est. completion: Jan 202133 patients

Phase 1/2Completed

NCT04610359 BiocorpMR-MC-01

Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis

Start: Oct 2020Est. completion: Dec 20223 patients

Phase 1Unknown

NCT01150565 AbbVieLiRIS low dose and LiRIS high dose

Safety Study of LiRIS in Interstitial Cystitis (IC) Patients

Start: Jul 2010Est. completion: Sep 201118 patients

Phase 1Completed

NCT05276466 MicroGenDXPolymerase Chain Reaction and Next-Generation DNA Sequencing

Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms

Start: Feb 2022Est. completion: Dec 2023100 patients

N/AUnknown

NCT02898220 Colorado TherapeuticsTrans-MAPP II Study of Urologic Chronic Pelvin Pain

Trans-MAPP II Study of Urologic Chronic Pelvin Pain

Start: Sep 2016Est. completion: Jun 202272 patients

N/ACompleted

NCT02514265 Colorado TherapeuticsTrans-MAPP Symptom Patterns Study (SPS)

Trans-MAPP Symptom Patterns Study (SPS)

Start: Jul 2015Est. completion: Jun 2020640 patients

N/ACompleted

NCT01378754 Grace MedicalFospropofol

Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia

Start: Jun 2011Est. completion: Jun 20140

N/AWithdrawn

NCT00590473 MedtronicInterstim

Sacral Neuromodulation in Patients With IC

Start: Apr 2007Est. completion: Feb 200932 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,806 patients

14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.